Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia

Liver Transplantation

Volumn 17, Issue 3, 2011, Pages 331-333

  Moreno, Ana ^a   Fortún, Jesús ^a   Graus, Javier ^a   Rodriguez Gandía, Miguel A ^a   Quereda, Carmen ^a   Pérez Elías, María J ^a   Nuño, Javier ^a   Wikman, Philip ^a   Moreno, Santiago ^a   Bárcena, Rafael ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; BICARBONATE; EMTRICITABINE; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RALTEGRAVIR; ROSUVASTATIN; STEROID; TACROLIMUS; TENOFOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTERY STEAL SYNDROME; ARTICLE; CASE REPORT; CHOLESTASIS; CYTOMEGALOVIRUS INFECTION; DELTA AGENT HEPATITIS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUID THERAPY; GLOMERULUS FILTRATION RATE; GLUCOSURIA; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERSPLENISM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALAISE; MALE; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RHABDOMYOLYSIS; SPLEEN ARTERY; VIRAL CLEARANCE; WALKING DIFFICULTY; WEAKNESS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DYSLIPIDEMIAS; FLUOROBENZENES; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; PYRIMIDINES; RHABDOMYOLYSIS; SEVERITY OF ILLNESS INDEX; SULFONAMIDES;

EID: 79952379376     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22225     Document Type: Article

References (15)

1. Watt KD, Charlton MR,. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010; 53: 199-206.
2. Anuurad E, Semrad A, Berglund L,. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord 2009; 7: 401-410.
3. Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS 2010; 24: 77-83.
4. Armitage J,. The safety of statins in clinical practice. Lancet 2007; 370: 1781-1790. (Pubitemid 350137473)
5. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106: 1024-1028. (Pubitemid 34925341)
6. Kostapanos MS, Milionis HJ, Elisaf MS,. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 2010; 10: 11-28.
7. Tzeng TB, Schneck DW, Birmingham BK, Mitchell PD, Zhang H, Martin PD, Kung LP,. Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidemia. Curr Med Res Opin 2008; 24: 2575-2585.
8. Simonson SG, Martin PD, Mitchell P, Schneck DW, Lasseter KC, Warwick MJ,. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol 2003; 58: 669-675. (Pubitemid 36363295)
9. Mikhail N, Iskander E, Cope D,. Rhabdomyolysis in an HIV-infected patient on antiretroviral therapy precipitated by high-dose pravastatin. Curr Drug Saf 2009; 4: 121-122.
10. Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y,. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone and atazanavir. J Am Board Fam Med 2007; 20: 411-416. (Pubitemid 47173856)
11. Issentress (raltegravir) [package insert]. Whitehouse Station, NJ: Merck; 2008.
12. Zembower TR, Gerzenshtein L, Coleman K, Palella FJ Jr,. Severe rhabdomyolysis associated with raltegravir use. AIDS 2008; 22: 1382-1383.
13. Tricot L, Teicher E, Peytavin G, Zucman D, Conti F, Calmus Y, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9: 1946-1952.
14. Moreno A, Pérez-Elías MJ, Casado JL, Fortún J, Bárcena R, Quereda C, et al. Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation. Liver Transpl 2010; 16: 530-532.
15. Dopazo C, Bilbao I, Lázaro JL, Sapisochin G, Caralt M, Blanco L, et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. Transplant Proc 2009; 41: 1021-1024.